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INTRODUCTION 
Method validation is the process by which it is established 
that performance characteristics of the method meet the 
requirements for the intended analytical applications. 
Methods need to be validated or revalidated before their 
introduction into routine use.
1 
The International 
Conference on Harmonization (ICH) of Technical 
Requirements for the Registration of Pharmaceuticals for 
Human Use
2
 has developed a text on the validation of 
analytical procedures. The United States Food and Drug 
Administration (USFDA) have proposed guidelines on 
submitting samples and analytical data for methods 
validation
5-7
. The United States Pharmacopoeia (USP) has 
published specific guidelines for method validation for 
compound evaluation
8
. The document includes definitions 
for eight validation characteristics. An extension with 
more detailed  
Methodology is in preparation and nearly completed
3
. The 
United States Environmental Protection Agency (US EPA) 
prepared a guidance for methods development and 
validation for the Resource Conservation and Recovery 
Act (RCRA)
4
. The pharmaceutical industry uses 
methodology published in the literature 
9,10
. The most 
comprehensive document was published as the 
„Conference Report of the Washington Conference on 
Analytical Methods Validation: Bioavailability, 
Bioequivalence and Pharmacokinetic Studies held in 1990 
(sponsored by the American Association of 
Pharmaceutical Scientists, the AOAC and the US FDA, 
among others)
10
. The report presents guiding principles for 
validation of studies in both human and animal subjects 
that may be referred to in developing future formal 
guidelines. Representatives of the pharmaceutical and 
chemical industry have published papers on the validation 
of analytical methods. Hokanson 
11,12
 applied the life cycle 
approach, developed for computerized systems, to the 
validation and revalidation of methods. Green
13
 gave a 
practical guide for analytical method validation with a 
description of a set of min imum requirements for a 
method. Renger and his colleagues 
14
 described the 
validation of a specific analytical procedure for the 
analysis of theophylline in a tablet using high performance 
thin layer chromatography (HPTLC). The validation 
procedure in that article is based on requirements for 
European Union mult istate registration. Wegscheider 
15
 
has published procedures for method validation with 
special focus on calibration, recovery experiments, method 
comparison and investigation of ruggedness. The 
Association of Official Analytical Chemists (AOAC) 
16 
has 
developed a Peer-Verified Methods validation program 
with detailed guidelines on what parameters should be 
validated. This article gives a review and a strategy for the 
validation of analytical methods for both in-house 
developed as well as standard methods and a 
recommendation on the documentation that should be 
produced during and at the end of method validation.  
Definition: 
•Documented evidence that the manufacturing process 
consistently produces product that  meets predetermined  
specifications. 
•Manufacturing process validation consists of successfully 
manufacturing at least threefull-scale batches in 
succession, which pass all in -process and product quality 
attributes. 
VALIDATION PROCESS  
The validation process consists of identifying and testing 
all aspects of a process that could affect the final test or 
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product. Prior to the testing of a process, the system must 
be properly qualified. Qualification includes the following 
steps: (These steps are common practice for equipment IQ, 
OQ and PQ).
17 
 Design qualification (DQ)- Defines the functional 
and operational specification of the instrument, 
program, or equipment and details the rationale for 
choosing the supplier. 
 Installation qualification (IQ) – Demonstrates that the 
process or equipment meets all specifications, is 
installed correctly, and all required components and 
documentation needed for continued operation are 
installed and in place. 
 Operational qualificat ion (OQ) – Demonstrates that 
all facets of the process or equipment are operating 
correctly. 
 Performance qualification (PQ) – Demonstrates that 
the process or equipment performs as intended in a 
consistent manner over time. 
 Component qualification (CQ) – is a relat ively new 
term developed in 2005. This term refers to the 
manufacturing of auxiliary components to ensure that 
they are manufactured to the correct design criteria. 
This could include packaging components such as 
folding cartons, shipping cases, labels or even phase 
change material. All of these components must have 
some type of random inspection to ensure that the 
third party manufacturer's process is consistently 
producing components that are used in the world of 
GMP at drug or b iologic manufacturer.  
TYPES OF VALIDATION 
 Equipment validation 
 Process validation 
 Analytical method validation  
 Cleaning validat ion 
EQUIPMENT VALIDATION 
          Installation Qualificat ion(IQ) 
          Operational Qualificat ion(OQ) 
          Performance Qualification(PQ) 
Installation Qualification (IQ) 
This is the first step in validation. This protocol insures 
that the system/equipment and its components areinstalled 
correctly and to the original manufacturer‟s specifications. 
Calibrat ion of major equipment, accessory equipment, 
and/or utilities shouldbe performed in this step as well 
IQ provides documented evidence that the equipment or 
system has been developed, supplied and installed in  
accordance with design drawings, the supplier's 
recommendations and In-house requirements. 
Furthermore, IQ ensures that a record of the principal 
features of the equipment or system, as installed, is 
available and that it is supported by sufficient adequate 
documentation to enable satisfactory operation, 
maintenance and change control to be implemented.
18 
Operational Qualification (OQ) 
This step proceeds after the IQ has been performed. In the 
OQ, tests are performed on the critical parameters of 
thesystem/process. These are usually the independent 
and/or manipulated variables associated with the 
system/equipment.
5-7
 All tests data and measurements must 
be documented in order to set a baseline for the 
system/equipment. OQ provides documented evidence that 
the equipment operates as intended throughout the 
specified design, operational or approved acceptance range 
of the equipment, as applicable. In cases where process 
steps are tested, a suitable placebo batch will be used to 
demonstrate equipment functionality. All new equipment 
should be fully commissioned prior to commencing OQ to 
ensure that as a minimum the equipment is safe to operate, 
all mechanical assembly and pre-qualification checks have 
been completed, that the equipment is fully functional and 
that documentation is complete.
13-15
  
Performance Qualification (PQ):  
This is the third and final phase of validation. This phase 
tests the ability of the process to perform over long periods 
of time within tolerance deemed acceptable. PQ is 
performed on the manufacturing process as a whole. 
Individual components of the system are not tested 
individually. The purpose of PQ is to provide documented 
evidence that the equipment can consistently achieve and 
maintain its performance specifications over a prolonged 
operating period at a defined operating point to produce a 
product of pre-determined quality. The performance 
specification will reference process parameters, in-process 
and product specifications.
20-22
 PQ requires three product 
batches to meet all acceptance criteria fo r in -process and 
product testing. For utility systems, PQ requires the utility 
medium to meet all specifications over a prolonged 
sampling period.
3-5 
PROCESS  VALIDATION 
“Process validation” is  establishing documented evidence 
whichprovides a high degree of assurance that a specific 
process consistentlyproduce a product meeting it‟s 
predetermined specifications and quality attributes”5,6 
Types of Process Validation 
o Prospective validation 
o Retrospective validation 
o Concurrent validation  
o Revalidation 
Prospective validation: 
Is defined as the establishment of documented evidence 
that a system does what it purports to do based on pre-
planned protocol. This validation is usually carried out 
prior to the introduction of new drugs and their 
manufacturing process. This approach to validation is 
normally undertaken whenever a new formula, process or 
facility must be validated before routine pharmaceutical 
formulat ion commences.
20,21
  In Prospective Validation, 
the validation protocol is executed before the process is put 
into commercial use. During the product development 
phase the production process  should be broken down into 
individual steps. Each step should be evaluated on the 
basis of experience or theoretical considerations to 
determine the critical parameters  that may affect the 
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quality of the finished product. A series of experiments 
should be designed to determine the crit icality of these 
factors. Each experiment should be planned and 
documented fully in an authorized protocol. All 
equipment, production environment and the analytical 
testing methods to be used should have been fully 
validated. Master batch documents can be prepared only 
after the critical parameters of the process have been 
identified and machine settings, component specifications 
and environmental conditions have been determined. It is 
generally considered acceptable that three consecutive 
batches/runs within the finally agreed parameters, giving 
product of the desired quality would constitute a proper 
validation of the process. It is a confirmation on the 
commercial three batches  before marketing. Upon 
complet ion of the review, recommendations should be 
made on the extent of monitoring and the in-process 
controls necessary for routine production. These should be 
incorporated into the batch manufacturing and packaging 
record or into appropriate standard operating procedures. 
Limits, frequencies and actions to be taken in the event of 
the limits being exceeded should be specified. It may be 
possible and acceptable in particular circumstances for a 
manufacturer that uses the same process for several related 
products to develop a scientifically sound validation plan 
for that process rather than different plans for each product 
manufactured by that process.
13,14 
Retrospective validation:  
The retrospective validation option is chosen for 
established products whose manufacturing processes are 
considered stable and when on the basis of economic 
considerations alone and resource limitations, prospective 
validation programs cannot be justified. Prior to 
undertaking retrospective validation, wherein the 
numerical in-process and/or end-product test data of 
historic production batches are subjected to statistical 
analysis, the equipment, facilit ies and subsystems used in 
connection with the manufacturing process must be 
qualified in conformance with CGMP requirements.
14-17
 
The basis for retrospective validation is stated in 21CFR 
211.110(b): “Valid in-process specifications for such 
characteristics shall be consistent with drug product final 
specifications and shall be derived from previous 
acceptable process average and process variability 
estimates where possible and determined by the 
application of suitable statistical procedures where 
appropriate.” Using either data-based computer systems or 
manual methods, retrospective validation may be 
conducted in the following manner:
18 
1. Gather the numerical data from the completed batch 
record and include assay values, end-product test results, 
and in-process data. 
2. Organize these data in a chronological sequence 
according to batch manufacturing data, using a spreadsheet 
format. 
3. Include data from at least the last 20–30 manufactured 
batches for analysis. If the number of batches is less than 
20, then include all manufactured batches and commit to 
obtain the required number for analysis. 
4. Trim the data by eliminating test results from noncritical 
processing steps and delete all gratuitous numerical 
informat ion. 
5. Subject the resultant data to statistical analysis and 
evaluation. 
6. Draw conclusions as to the state of control of the 
manufacturing process based on the analysis of 
retrospective validation data. 
7. Issue a report of your findings (documented evidence).  
Concurrent validation: 
 In-process monitoring of critical processing steps and end-
product testing of current production can provide 
documented evidence to show that the manufacturing 
process is in a state of control. Is similar to prospective, 
except the operating firm will sell the product during the 
qualification runs, to the public at its market price.
19
 This 
validation involves in process monitoring of critical 
processing steps and product testing. Retrospective 
validation is only acceptable for well established detailed 
processes that include operational limits for each critical 
step of the process and will be inappropriate where there 
have been recent changes in the formulat ion of the 
product, operating procedures, equipment and facility. The 
source of data for retrospective validation should include 
amongst others, batch documents, process control charts, 
maintenance log books, process capability studies, finished 
product test results, including trend analyses, and stability 
results. For the purpose of retrospective validation studies, 
it is considered acceptable that data from a minimum of 
ten consecutive batches produced be utilized. When less 
than ten batches are available, it is considered that the data 
are not sufficient to demonstrate retrospectively that the 
process is fully under control. In such cases the study 
should be supplemented with data generated with 
concurrent or prospective validation.
7-9
 
Some of the essential elements for Retrospective 
Validation are: 
• Batches manufactured for a defined period (minimum of 
10 last consecutive batches). 
• Number of lots released per year.  
• Batch size/strength/manufacturer/year/period. 
• Master manufacturing/packaging documents. 
• Current specifications for active materials/fin ished 
products. 
• List of process deviations, corrective actions and changes 
to manufacturing documents. 
• Data for stability testing for several batches. 
• Trend analyses including those for quality related 
complaints. 
Revalidation: 
Almost all GMP texts recommend that whenever there are 
significant changes in the facility, equipment or process, 
revalidation should be carried out. The FDA process 
validation guidelines refer to a quality assurance system in  
place that requires revalidation whenever there are changes 
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in packaging (assumed to be the primary container-closure 
system), formulation, equipment or processes (meaning 
not clear) which could impact on product effectiveness or 
product characteristics and whenever there are changes in 
product characteristics. 
Conditions requiring revalidation study and documentation 
are listed as follows:
11 
 Change in a critical component (usually refers to raw 
materials). 
 Change or replacement in a critical piece of modular 
(capital) equipment. 
 Change in a facility and/or plant (usually location or 
site). 
 Significant (usually order of magnitude) increase or 
decrease in batch size  
Sequential batches that fail to meet product and 
process specifications. 
Benefits of process validation 
• Increased throughput 
• Reduction in rejections and reworks  
• Reduction in utility costs 
• Avoidance of capital expenditures  
• Fewer complaints about process related failures  
• Reduced testing in process and finished goods 
• More rap id and accurate investigations into process 
deviations 
• More rapid and reliab le start-up of new equipment 
• Easier scale-up from development work 
• Easier maintenance of the equipment 
• Improved employee awareness of processes 
• More rapid automat ion 
ANALYTICAL METHOD VALIDATION: 
There are many reasons for the need to validate analytical 
procedures. Among them are regulatory requirements, 
good science, and quality control requirements. The Code 
of Federal Regulations (CFR) 311.165c exp licitly states 
that “the accuracy, sensitivity, specificity, and 
reproducibility of test methods employed by the firm shall 
be established and documented.”Of course, as scientists, 
we would want to apply good science to demonstrate that 
the analytical method used had demonstrated accuracy, 
sensitivity, specifi city, and reproducibility. Finally  
management of the quality control unit would definitely  
want to ensure that the analytical methods that the 
department uses to release its products are properly 
validated for its intended use so the product will be safe for 
human use.
1-3
 
Analytical methods need to be validated, verified, or 
revalidated in the fo llowing instances: 
 Before in itial use in routine testing  
 When transferred to another laboratory  
 Whenever the conditions or method parameters for 
which the method has been validated change (for 
example, an instrument with different characteristics 
or samples with a different matrix) and the change is 
outside the original scope of the method.
7
  
Cycle of analytical methods  
The analytical method validation activity is not a one - 
time study. An analytical method will be developed and 
validated for use to analyze samples during the early 
development of an active pharmaceutical ingredient (API) 
or drug product. As drug development progresses from 
phase 1 to commercializat ion, the analytical method will 
follow a similar progression. The final method will be 
validated for its intended use for the market image drug 
product and transferred to the quality control laboratory for 
the launch of the drug product. However, if there are any 
changes in the manufacturing process that have the 
potential to change the analytical profile o f the drug 
substance and drug product, this validated method may 
need to be revalidated to ensure that it is still suitable to 
analyze the API or drug product for its intended purpose.
5-8
 
 
Strategy for Validation of Methods 
The validity of a specific method should be demonstrated 
in laboratory experiments using samples or standards that 
are similar to the unknown samples analyzed in the 
routine. The preparation and execution should follow a 
validation protocol, preferably written in a step by step 
instruction format. Possible steps for a complete method 
validation are listed below.  
Steps in Method Validation 
1. Develop a validation protocol or operating procedure for 
the Validation  
2. Define the applicat ion, purpose and scope of the method  
3. Define the performance parameters and acceptance 
criteria  
4. Define validation experiments  
5. Verify relevant performance characteristics of 
equipment  
6. Qualify materials, e.g. standards and reagents  
7. Perform pre-validation experiments  
8. Adjust method parameters or/and acceptance criteria if 
necessary  
9. Perform full internal (and external) validation 
experiments  
10. Develop SOPs for executing the method in the routine  
11. Define criteria for revalidation  
12. Define type and frequency of sys tem suitability tests 
and/or analytical quality control (AQC) checks for the 
routine  
13. Document validation experiments and results in the 
validation.     
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Parameters For Method Validation: 
The parameters as defined by the ICH
2, 3
 and by other 
organizations and authors are Specificity, selectivity, 
precision, repeatability, intermediate precision, 
reproducibility, accuracy, trueness, bias, linearity range, 
limit of detection, limit of quantitation, robustness and 
ruggedness.  
Selectivity / S pecificity 
The terms selectivity and specificity are often used 
interchangeably. A detailed discussion of this term as 
defined by different organizat ions has been made by 
Vessmann 
17
. Even inconsistent with ICH, the term 
specific generally refers to a method that produces a 
response for a single analyte only, while the term selective 
refers to a method which provides responses for a number 
of chemical entities that may or may not be distinguished 
from each other. If the response is distinguished from all 
other responses, the method is said to be selective. Since 
there are very few methods that respond to only one 
analyte, the term selectivity is usually more appropriate.  
The USP monograph 
8
 defines selectivity of an analytical 
method as its ability to measure accurately an analyte in  
the presence of interference, such as synthetic precursors, 
excip ients, enantiomers and known (or likely) degradation 
products that may be expected to be present in the sample 
matrix.  
Determination:- 
In the case of qualitative analyses, the ability to select 
between compounds of closely related structure that are 
likely to be present should be demonstrated. This should 
be confirmed by obtaining positive results from samples 
containing the analyte, coupled with negative results from 
samples that do not contain the analyte and by confirming 
that a positive response is not obtained from materials 
structurally similar to or closely related to the analyte.
21
  
Selectiv ity in liquid chromatography is obtained by 
choosing optimal columns and setting chromatographic 
conditions such as mobile phase composition, column 
temperature and detector wavelength. It is a difficult task 
in chromatography to ascertain whether the peaks within a 
sample chromatogram are pure or consist of more than one 
compound. While in the past chromatographic parameters 
such as mobile phase composition or the column has been 
modified. More recently the applications of spectroscopic 
detectors coupled on-line to the chromatograph have been 
suggested
3,5
 The principles of diode-array detection in 
HPLC and their application and limitations to peak purity 
are described in the literature 
19-21
.  
Precisions and Reproducibility 
The precision of a method is the extent to which the 
individual test results of multiple inject ions of a series of 
standards agree. The measured standard deviation can be 
subdivided into three categories: repeatability, 
intermediate precision and reproducibility
2, 3
.  
Repeatability is obtained when one operator using one 
piece of equipment over a relatively short time -span 
carries out the analysis in one laboratory. At least 5 or 6 
determinations of three different matrices at two or three 
different concentrations should be done and the relative 
standard deviation calculated.  
Intermediate precision is a term that has been defined by 
ICH
2
 as the long-term variab ility of the measurement 
process and is determined by comparing the results of a 
method run within a single laboratory over a number of 
weeks. A method‟s intermediate precision may reflect  
discrepancies in results obtained by different operators, 
from different instruments, with standards and reagents 
from different suppliers, with columns from different 
batches or a combination of these.  
Objective of intermediate precision validation is to verify 
that in the same laboratory the method will provide the 
same results once the development phase is over.  
Reproducibility as defined by ICH
2, 3
 represents the 
precision obtained between laboratories. Objective is to 
verify that the method will prov ide the same results in 
different laboratories.  
Accuracy and recovery 
The accuracy of an analytical method is the extent to 
which test results generated by the method and the true 
value agree. The true value for accuracy assessment can be 
obtained in several ways.  
Determination:-In case of a drug substance, accuracy may 
be determined by application of the analytical method to 
an analyte of  known purity or by comparison of the results 
with well characterized method ,the accuracy of which has 
been stated or defined.
17,18
    
Linearity and calibration curve  
The linearity of an analytical method is its ability to elicit  
test results that are (directly or by means of well-defined 
mathematical transformations) proportional to the 
concentration of analytes in samples within a g iven range. 
Linearity is determined by a series of three to six injections 
of five or more standards whose concentrations span 80-
120 percent of the expected concentration range. The 
response should be (directly or by means of a well-defined 
mathematical calculation) proportional to the 
concentrations of the analytes. A linear regression equation 
applied to the results should have an intercept not 
significantly different from zero. If a significant nonzero  
intercept is obtained, it should be demonstrated that there 
is no effect on the accuracy of the method.
17,18
  
Range 
The range of an analytical method is the interval between 
the upper and lower levels (including these levels) that 
have been demonstrated to be determined with precision, 
accuracy and linearity using the method as written. The 
range is normally expressed in the same units as the test 
results (e.g. percentage, parts per million) obtained by the 
analytical method.  
The range of the method is validated by verify ing that the 
analytical method provides acceptable precision, accuracy 
and linearity when applied to samples containing analyte at 
the extremes of the range as well as within the range.  
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Limit of detection:  
It is the lowest concentration of analyte in a sample that 
can be detected but not necessarily quantified. In  
chromatography the detection limit is the injected amount 
that results in a peak with a height at least twice or three 
times as high as the baseline noise level.
16
  
Determination:- 
the detection limit is generally determined by the analysis 
of samples with known concentration of analyte and by 
establishing the minimum level at which the analyte can be 
reliably detected.
21
  
Limit of quantitation: 
It is the minimum injected amount that gives precise 
measurements, in chromatography typically requiring peak 
heights 10 to 20 times higher than baseline noise.  
Ruggedness 
Ruggedness is measure of reproducibility test results under 
the variation in conditions normally expected from 
laboratory to laboratory and from analyst to analyst.
13
  
The Ruggedness of an analytical method is degree of 
reproducibility of test results obtained by the analysis of 
the same samples under a variety of conditions, such as; 
different laboratories, analysts, instruments, reagents, 
temperature, t ime etc.  
Robustness 
Robustness of analytical method is a measure of its 
capacity to remain unaffected by small but deliberate 
variations in method parameters and provides an indication 
of its reliability during normal usage.
15
  
CLEANING VALIDATION 
Cleaning validation is a documented process that proves 
the effectiveness and consistency in cleaning a 
pharmaceutical production equipment1. Validations of 
equipment clean ing procedures are main ly used in 
pharmaceutical industries to prevent cross contamination 
and adulteration of drug products hence is critically  
important. The prime purpose of validating a clean ing 
process is to ensure compliance with federal and other 
standard regulations. The most important benefit of 
conducting such a validation work is the identification and 
correction of potential problems previously unsuspected, 
which could compromise the safety, efficacy or quality of 
subsequent batches of drug product produced within the 
equipment. The object ives of equipment cleaning and 
cleaning validation in an Active Pharmaceutical Ingredient 
(API) area are same as those in pharmaceutical production 
area. In both these areas efforts are necessary to prevent 
contamination of a future batch with the previous batch 
material. The cleaning of 'difficult to reach' surface is one 
of the most important consideration in equipment cleaning 
validation. Equipment cleaning validation in an API 
facility is extremely important as cross contamination in 
one of the pharmaceutical dosage forms, will multip ly the 
problem.
15-18
  
 
 
Cleaning Procedures 
Standard cleaning procedures for each piece of equipment 
and process should be prepared. It is vital that the 
equipment design is evaluated in detail in conjunction with 
the product residues which are to be removed, the 
available cleaning agents and cleaning techniques, when 
determining the optimum clean ing procedure for the 
equipment.
20 
Testing methods  
The basic requirements of the analytical methods should 
have the following criteria. 
1. Testing method should have the ability to detect target 
substances at levels consistent with the acceptance criteria. 
2. Testing method should have the ability to detect target 
substances in the presence of other materials that may also 
be present in the sample. 
3. The testing analytical method should include a 
calculation to convert the amount of residue detected in the 
sample to 100% if the recovery data generated indicates a 
recovery outside 
the allowed range.
18-20 
Analyzing cleaning validation samples  
There are many analytical techniques available that can be 
used in cleaning validation. But choosing the appropriate 
analytical tool depends on a variety of factors . The most 
important factor is to determine the specifications or 
parameters to be measured. The limit should always be 
established prior to the selection of the analytical tool.
19 
Specific and non-specific methods 
A specific method detects unique compounds in the 
presence of potential contaminants. Ex: HPLC. Non-
specific methods are those methods that detect any 
compound that produces a certain response 
Ex: Total Organic Carbon (TOC), pH and conductivity.
19,20 
IMPORTANCE OF VALIDATION 
The most compelling reasons to optimize and validate 
pharmaceutical productions and supporting processes are 
quality assurance and cost reduction .the basic princip les 
of quality assurance has as their goal and the production of 
articles that are fit for there intended use.
10
   These 
principles are Quality, safety, and effectiveness must be 
designed and built in to the product, quality cannot be 
inspected or tested in the finished products and each step 
of the manufacturing process must be controlled to 
maximize the probability that the fin ished product meets 
all quality and design specification. The relationship of 
quality assurance and process validation goes well beyond 
the responsibility of any quality assurance functions, 
nevertheless it is fair to say that process validation is a 
quality assurance tool because it is establishes a quality 
standard for the specific process. 
CONCLUS ION: 
Quality control is the part of GMP, it is concerned with the 
sampling specification, testing and with organizat ion 
documentation and release procedures.
 
Where as assurance 
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of quality is derived from careful attention to a number of 
factors including selection of quality materials, 
equipments, adequate product, process design ,selection of 
approved vendors, proper GMP inspections , employee 
training ,technical audit, critical evaluation of market  
complaints, in-process control of processes, and end 
product testing.
 
Process validation should result in fewer 
product recalls and trouble shooting .process consistently 
under control requires less process support, will  have less 
down time, fewer batch failu res , and may operate more 
efficiently with greater output .In addition timely and 
appropriate validation improves quality assurance ,reduces 
cost by process optimization ,enables more effect ive and 
rapid trouble shooting ,shortens lead time lead ing to low 
inventories ,empowers all employees to control their 
processes and to improve them ,enables better system 
control ,maintains, and improves a high degree of 
assurance that specific process will consistently produce a 
product meetings its predetermined specifications and 
quality characteristics. 
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